

1631
RECEIVED

MAY 30 2002

In re Patent Application of

Atty Dkt. 2752-15

MAERTENS et al.

C# M#


Serial No. 09/638,693

Group Art Unit: 1631

Filed: August 15, 2000

Examiner: Martinell

Date: May 28, 2002

Title: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS
THERAPEUTIC AND DIAGNOSTIC AGENTSAssistant Commissioner for Patents
Washington, DC 20231TECH CENTER 1600/2900
RECEIVED
MAY 29 2002

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 110.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 110.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00


TOTAL FEE ENCLOSED \$ 110.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:b

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 



RECEIVED

THE UNITED STATES PATENT AND TRADEMARK OFFICE MAY 30 2002

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2752-15

Serial No. 09/638,693

Group: 1631

Filed: August 15, 2000

Examiner: Martinell

TECH CENTER 1600/2900
#15/D
BP
6-6-02

For: NEW SEQUENCES OF HEPATITIS C VIRUS
GENOTYPES AND THEIR USE AS THERAPEUTIC AND
DIAGNOSTIC AGENTS

* * * * *

Tuesday, May 28, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

Responsive to the Communication dated March 25, 2002, entry and consideration of the following amendments and remarks, as well as the attached, are requested; the period for response having been extended up to and including May 28, 2002, by submission of the requisite petition and fee, attached.

IN THE CLAIMS:

Amend the claims as follows.

Sub H7
D/

57. (Amended) An HCV type 5 polypeptide or peptide selected from the region spanning positions 1 to 2757 of HCV type 5, and wherein said peptide or polypeptide is obtainable by expression of amplified HCV type 5 specific polynucleic acids using HCV type 5 specific primers,
and wherein said peptide or polypeptide contains at least one genotype-specific amino acid.

05/29/2002 BABRAHA1 00000104 09638693

01 FC:115

110.00 DP

631757